206 related articles for article (PubMed ID: 36711519)
1. Adrenomedullin 2/intermedin is a slow off-rate, long-acting endogenous agonist of the adrenomedullin
Babin KM; Karim JA; Gordon PH; Lennon J; Dickson A; Pioszak AA
bioRxiv; 2023 Jan; ():. PubMed ID: 36711519
[TBL] [Abstract][Full Text] [Related]
2. Adrenomedullin 2/intermedin is a slow off-rate, long-acting endogenous agonist of the adrenomedullin
Babin KM; Karim JA; Gordon PH; Lennon J; Dickson A; Pioszak AA
J Biol Chem; 2023 Jun; 299(6):104785. PubMed ID: 37146967
[TBL] [Abstract][Full Text] [Related]
3. Variable CGRP family peptide signaling durations and the structural determinants thereof.
Babin KM; Gostynska SE; Karim JA; Pioszak AA
Biochem Pharmacol; 2024 Jun; 224():116235. PubMed ID: 38670438
[TBL] [Abstract][Full Text] [Related]
4. Structure-function analyses reveal a triple β-turn receptor-bound conformation of adrenomedullin 2/intermedin and enable peptide antagonist design.
Roehrkasse AM; Booe JM; Lee SM; Warner ML; Pioszak AA
J Biol Chem; 2018 Oct; 293(41):15840-15854. PubMed ID: 30139742
[TBL] [Abstract][Full Text] [Related]
5. Adrenomedullin 2/intermedin in the hypothalamo-pituitary-adrenal axis.
Takahashi K; Morimoto R; Hirose T; Satoh F; Totsune K
J Mol Neurosci; 2011 Feb; 43(2):182-92. PubMed ID: 20596793
[TBL] [Abstract][Full Text] [Related]
6. Biochemical characterization of G protein coupling to calcitonin gene-related peptide and adrenomedullin receptors using a native PAGE assay.
Roehrkasse AM; Warner ML; Booe JM; Pioszak AA
J Biol Chem; 2020 Jul; 295(28):9736-9751. PubMed ID: 32487746
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of components of the cardiomyocyte adrenomedullin/intermedin receptor system following blood pressure reduction in nitric oxide-deficient hypertension.
Zhao Y; Bell D; Smith LR; Zhao L; Devine AB; McHenry EM; Nicholls DP; McDermott BJ
J Pharmacol Exp Ther; 2006 Mar; 316(3):1269-81. PubMed ID: 16326922
[TBL] [Abstract][Full Text] [Related]
8. Expression of adrenomedullin 2/intermedin in human adrenal tumors and attached non-neoplastic adrenal tissues.
Morimoto R; Satoh F; Murakami O; Hirose T; Totsune K; Imai Y; Arai Y; Suzuki T; Sasano H; Ito S; Takahashi K
J Endocrinol; 2008 Jul; 198(1):175-83. PubMed ID: 18460550
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of intermedin/adrenomedullin-2 in a cellular model of human pulmonary arterial hypertension.
Holmes D; Corr M; Thomas G; Harbinson M; Campbell M; Spiers P; Bell D
Peptides; 2020 Apr; 126():170267. PubMed ID: 32017948
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of exogenous adrenomedullin and CGRP in Ramp and Calcrl deficient mice.
Pawlak JB; Wetzel-Strong SE; Dunn MK; Caron KM
Peptides; 2017 Feb; 88():1-7. PubMed ID: 27940069
[TBL] [Abstract][Full Text] [Related]
11. Expression of adrenomedullin 2/intermedin, a possible reno-protective peptide, is decreased in the kidneys of rats with hypertension or renal failure.
Hirose T; Totsune K; Mori N; Mori T; Morimoto R; Metoki H; Asayama K; Kikuya M; Ohkubo T; Kohzuki M; Takahashi K; Imai Y
Am J Physiol Renal Physiol; 2010 Jul; 299(1):F128-34. PubMed ID: 20462970
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of intermedin on cardiovascular, pulmonary and renal diseases: comparison with adrenomedullin and CGRP.
Holmes D; Campbell M; Harbinson M; Bell D
Curr Protein Pept Sci; 2013 Jun; 14(4):294-329. PubMed ID: 23745696
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of adrenomedullin 2/intermedin mediated vasorelaxation in rat main pulmonary artery.
Telli G; Erac Y; Tel BC; Gumusel B
Peptides; 2018 May; 103():65-71. PubMed ID: 29588171
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of adrenomedullin 2/intermedin in rat hearts with congestive heart failure.
Hirose T; Totsune K; Mori N; Morimoto R; Hashimoto M; Nakashige Y; Metoki H; Asayama K; Kikuya M; Ohkubo T; Hashimoto J; Sasano H; Kohzuki M; Takahashi K; Imai Y
Eur J Heart Fail; 2008 Sep; 10(9):840-9. PubMed ID: 18692436
[TBL] [Abstract][Full Text] [Related]
15. Structure-function analysis of amino acid 74 of human RAMP1 and RAMP3 and its role in peptide interactions with adrenomedullin and calcitonin gene-related peptide receptors.
Qi T; Ly K; Poyner DR; Christopoulos G; Sexton PM; Hay DL
Peptides; 2011 May; 32(5):1060-7. PubMed ID: 21402116
[TBL] [Abstract][Full Text] [Related]
16. Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function.
Qi T; Christopoulos G; Bailey RJ; Christopoulos A; Sexton PM; Hay DL
Mol Pharmacol; 2008 Oct; 74(4):1059-71. PubMed ID: 18593822
[TBL] [Abstract][Full Text] [Related]
17. Receptor activity-modifying protein-dependent effects of mutations in the calcitonin receptor-like receptor: implications for adrenomedullin and calcitonin gene-related peptide pharmacology.
Watkins HA; Walker CS; Ly KN; Bailey RJ; Barwell J; Poyner DR; Hay DL
Br J Pharmacol; 2014 Feb; 171(3):772-88. PubMed ID: 24199627
[TBL] [Abstract][Full Text] [Related]
18. Intermedin/adrenomedullin-2 acts within central nervous system to elevate blood pressure and inhibit food and water intake.
Taylor MM; Bagley SL; Samson WK
Am J Physiol Regul Integr Comp Physiol; 2005 Apr; 288(4):R919-27. PubMed ID: 15576658
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical localization of adrenomedullin 2/intermedin-like immunoreactivity in human hypothalamus, heart and kidney.
Takahashi K; Kikuchi K; Maruyama Y; Urabe T; Nakajima K; Sasano H; Imai Y; Murakami O; Totsune K
Peptides; 2006 Jun; 27(6):1383-9. PubMed ID: 16359754
[TBL] [Abstract][Full Text] [Related]
20. Adrenomedullin 2 (AM2)/intermedin is a more potent activator of hypothalamic oxytocin-secreting neurons than AM possibly through an unidentified receptor in rats.
Hashimoto H; Hyodo S; Kawasaki M; Shibata M; Saito T; Suzuki H; Otsubo H; Yokoyama T; Fujihara H; Higuchi T; Takei Y; Ueta Y
Peptides; 2007 May; 28(5):1104-12. PubMed ID: 17386959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
